Continent’s top firms drove most of European equity gains last year
Novartis
The shares dropped 4 per cent, tempering gains of 9 per cent so far this year, as analysts pointed to higher-than-expected costs and some disappointment over the 2024 goal.
Pharmaceutical-related products accounted for almost two-thirds of Irish goods exports last year
Higher interest rates and ESG requirements see Dublin 4 scheme’s capital value fall to below replacement cost level of €170 per square foot
Action against generics group Mylan continues after terms agreed with rival generics player Accord Healthcare in patent infringement case
When staff at the Irish arm of the Swiss pharma company Novartis were asked for feedback on wellness initiatives, health screening was high on the list
Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest pharma shake-up in decades
US consumer price index comes in marginally below expectations, with core prices as expected
The sector is dealing with a double whammy of an economic downturn and changes in working patterns
Agency’s figures also point to partial displacement of trade following UK’s exit from EU
Revenue fails to convince court that Swiss company should not be refunded
The medicine is used in the treatment of relapsing-remitting multiple sclerosis and contains the active ingredient fingolimod
Pharma group has moved to new global structure in 2022 in a bid to cut costs
Irish company’s software is designed to help make pathology more efficient
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices